What is the 13F Pro Quality Score for LPCN?

13F Pro ranks Lipocine Inc. (LPCN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LPCN's current score at https://13fpro.ai/company/LPCN (free sign-up required for the full ranking).

Where does 13F Pro source LPCN data?

All Lipocine Inc. fundamentals and ownership data come directly from SEC EDGAR. Lipocine Inc. files with the SEC under CIK 1535955. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LPCN in?

Lipocine Inc. (LPCN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LPCN research updated on 13F Pro?

LPCN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lipocine Inc.(LPCN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1535955 LPCN stock profile & AI dashboard →

13F Pro Quality Score

6.1/100

Rank #2,952 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LPCN Scores 6/100

exact factor attribution · 2026-09-11

LPCN's composite is held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

-1.6 pts

19th pct

Institutional flow

-2.2 pts

7th pct

Earnings growth

-2.2 pts

5th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-6.6 pts

6th pct

Free cash flow

-6.7 pts

5th pct

Scale

-7.0 pts

3th pct

Revenue growth

-9.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LPCN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Lipocine Inc. (LPCN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LPCN at 6.1/100 on a 32-signal composite quality model, placing it at rank #2,952 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lipocine Inc. reports quarterly revenue of $190.1K, net income of $-2.6M. Top institutional holders of LPCN by reported 13-F value include Squadron Capital Management, Ikarian Capital, Eversept Partners, based on the most recent SEC filings. LPCN trades on the Nasdaq exchange and files with the SEC under CIK 1535955. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LPCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lipocine Inc. directly from SEC EDGAR. Lipocine Inc.'s 13F Pro composite quality score has ranged between 6 and 25 since 2026, currently 6.1 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Lipocine Inc.

Quirks, history, and lore behind LPCN — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap pharmaceutical company · listed on Nasdaq · headquartered in Utah · focused on developing specialty drug formulations.
2
The Numbers
With revenue in the low single-digit millions and a market cap well under $100 million, this is a clinical-stage biotech where the pipeline is the whole story.
3
The History
Founded in the early 2000s, the company built its identity around a proprietary oral drug delivery technology designed to improve how the body absorbs poorly soluble compounds.
4
The Secret
Its platform, called LIPO technology, uses lipid-based formulations to ferry drugs through the gut — think of it as wrapping your medicine in a tiny fat droplet for a smoother ride.
5
The Lore
Its lead program has taken a long and bumpy road through the FDA, targeting testosterone replacement therapy for men — a crowded market it hoped to crack with a once-daily oral pill instead of gels or injections.
6
The Giveaway
Its very name is a mashup of lipid and medicine — a Utah biotech whose ticker starts with LPCN and whose entire existence is built around making testosterone therapy something you swallow, not slather.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$190.1K

Net Income

Q2 2026

$-2.6M

ROIC

Q2 2026

-52.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-82.3% YoY

$2.0MFY 2025

FY22 $500.0KFY23 $-2.9MFY24 $11.2MFY25 $2.0M

Net Income

-115371.9% YoY

$-9.6MFY 2025

FY22 $-10.8MFY23 $-16.4MFY24 $8.4KFY25 $-9.6M

Operating Income

-797.9% YoY

$-10.4MFY 2025

FY22 $-12.1MFY23 $-17.9MFY24 $-1.2MFY25 $-10.4M

EPS (Diluted)

$-1.69FY 2025

FY22 $-2.15FY23 $-3.14FY24 —FY25 $-1.69

Total Assets

-24.5% YoY

$17.0MFY 2025

FY22 $37.5MFY23 $23.0MFY24 $22.5MFY25 $17.0M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-699.3% YoY

$-9.8MFY 2025

FY22 $-12.0MFY23 $-11.9MFY24 $-1.2MFY25 $-9.8M

Free Cash Flow

—FY 2025

FY22 $-12.1MFY23 $-11.9MFY24 $-1.3MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.0M -82.3%	$11.2M +492.8%	$-2.9M -670.2%	$500.0K -96.9%	$16.1M	$0.00
Net Income	$-9.6M -115371.9%	$8.4K +100.1%	$-16.4M -52.0%	$-10.8M -1595.9%	$-634.4K +97.0%	$-21.0M
Operating Income	$-10.4M -797.9%	$-1.2M +93.6%	$-17.9M -48.0%	$-12.1M -485.3%	$3.1M +117.5%	$-18.0M
EPS (Diluted)	$-1.69	—	$-3.14 -46.0%	$-2.15 -21400.0%	$-0.01 +97.4%	$-0.38
Total Assets	$17.0M -24.5%	$22.5M -2.1%	$23.0M -38.7%	$37.5M -28.5%	$52.5M +107.0%	$25.4M
Total Debt	—	—	—	—	$4.0M -52.3%	$8.3M
Operating Cash Flow	$-9.8M -699.3%	$-1.2M +89.7%	$-11.9M +0.9%	$-12.0M -171.3%	$-4.4M +71.2%	$-15.3M
Free Cash Flow	—	$-1.3M +89.0%	$-11.9M +1.8%	$-12.1M -173.9%	$-4.4M	—

Get alerted when LPCN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lipocine Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LPCN

Squadron Capital Management LLC
$2.1M810,000 sh
Ikarian Capital, LLC
$1.3M508,556 sh
Eversept Partners, LP
$755.2K294,989 sh
VANGUARD CAPITAL MANAGEMENT LLC
$590.9K230,823 sh
ACADIAN ASSET MANAGEMENT LLC
$435.0K170,417 sh
BOOTHBAY FUND MANAGEMENT, LLC
$359.6K140,487 sh
JANE STREET GROUP, LLC
$243.8K95,227 sh
BlackRock, Inc.
$228.5K89,272 sh
TWO SIGMA INVESTMENTS, LP
$217.3K84,887 sh
CITADEL ADVISORS LLC
$207.9K81,221 sh

Fund	Value	Shares
Squadron Capital Management LLC	$2.1M	810,000
Ikarian Capital, LLC	$1.3M	508,556
Eversept Partners, LP	$755.2K	294,989
VANGUARD CAPITAL MANAGEMENT LLC	$590.9K	230,823
ACADIAN ASSET MANAGEMENT LLC	$435.0K	170,417
BOOTHBAY FUND MANAGEMENT, LLC	$359.6K	140,487
JANE STREET GROUP, LLC	$243.8K	95,227
BlackRock, Inc.	$228.5K	89,272
TWO SIGMA INVESTMENTS, LP	$217.3K	84,887
CITADEL ADVISORS LLC	$207.9K	81,221

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LPCN on your watchlist

Track score changes the day Lipocine Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LPCN a good stock to buy?

13F Pro's AI-powered analysis of Lipocine Inc. (LPCN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LPCN are available on the LPCN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LPCN is classified as a small company.

Which hedge funds own LPCN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LPCN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lipocine Inc.'s investment landscape.